2) Murrell DF, Dick S, Ahmed AR et al : Consensus statement on definitions of desease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol, 2008 ; 58 : 1043-1046.
3) Amagai M, Ikeda S, Shimizu H et al : A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol, 2009 ; 60 : 595-603.
4) Kwon EJ, Yamagami J, Nishikawa T, Amagai M : Anti-desmoglein IgG autoantibodies in patients with pemphigus in remission. J Eur Acad Dermatol Venereol, 2008 ; 22 : 1070-1075.
5) Salopek TG, Logsetty S, Tredget EE : Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder. J Am Acad Dermatol, 2002 ; 47 : 785-788.